SEC Form 8-K Summary
Business Context and Reporting Period
TriSalus Life Sciences, Inc. furnished a Form 8-K dated April 1, 2024 under Item 2.02 to announce a business update and financial results for the quarter and year ended December 31, 2023. The company is an emerging growth company, and its common stock and warrants trade on the Nasdaq Global Market under TLSI and TLSIW, respectively.
Financial Metrics
The filing states that the related press release includes financial results for the quarter and year ended December 31, 2023, but the provided filing text does not include clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
The financial information in the press release is unaudited and subject to change.
Material Changes Versus the Prior Comparable Period
The filing text does not provide sufficient financial data to determine material changes versus the prior comparable period.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing identifies a business update but does not provide specific guidance, outlook, risk disclosures, contingencies, or unusual items in the supplied text. The detailed business update and results were furnished as Exhibit 99.1.
The information was furnished, not filed, for purposes of Section 18 of the Exchange Act and is generally not subject to liability under that section or Sections 11 and 12(a)(2) of the Securities Act. It is not incorporated by reference into other SEC filings unless expressly referenced.
Key Facts for Investors to Verify
- Review Exhibit 99.1, the April 1, 2024 press release, for the omitted financial results and business update.
- Verify whether the reported financial information changed because it was unaudited and subject to revision.
- Confirm revenue, net loss, cash flow, cash balance, debt, liquidity, margins, and year-over-year comparisons from the press release or subsequent audited filings.
- Assess any guidance, operating milestones, financing needs, or risk disclosures contained in the complete exhibit.